Clinical Role of CA125 in Worsening Heart Failure: A BIOSTAT-CHF Study Subanalysis.

[1]  J. Lupón,et al.  CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction , 2020 .

[2]  A. Bayés‐Genís,et al.  Carbohydrate antigen 125 in heart failure. A New era in the monitoring and control of treatment , 2019, Medicina Clínica (English Edition).

[3]  A. Bayés‐Genís,et al.  Carbohydrate antigen 125 in heart failure. New era in the monitoring and control of treatment. , 2019, Medicina clinica.

[4]  N. Samani,et al.  Bio‐adrenomedullin as a marker of congestion in patients with new‐onset and worsening heart failure , 2019, European journal of heart failure.

[5]  G. Filippatos,et al.  The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology , 2019, European journal of heart failure.

[6]  A. Baranchuk,et al.  Cancer antigen-125 and outcomes in acute heart failure: a systematic review and meta-analysis , 2018, Heart Asia.

[7]  P. Ponikowski,et al.  Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. , 2018, International journal of cardiology.

[8]  A. Mebazaa,et al.  Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey. , 2017, JACC. Heart failure.

[9]  G. Fonarow,et al.  Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure , 2017, European heart journal. Acute cardiovascular care.

[10]  P. Ponikowski,et al.  Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure , 2017, European journal of heart failure.

[11]  S. Morell,et al.  Carbohydrate Antigen-125-Guided Therapy in Acute Heart Failure: CHANCE-HF: A Randomized Study. , 2016, JACC. Heart failure.

[12]  P. Ponikowski,et al.  A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT‐CHF , 2016, European journal of heart failure.

[13]  E. Núñez,et al.  Clinical utility of antigen carbohydrate 125 in heart failure , 2014, Heart Failure Reviews.

[14]  K. Swedberg,et al.  Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. , 2013, European heart journal.

[15]  E. Núñez,et al.  Antigen carbohydrate 125 in heart failure: not just a surrogate for serosal effusions? , 2011, International journal of cardiology.

[16]  G. Fonarow,et al.  Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. , 2010, European heart journal.

[17]  Patrick Royston,et al.  Multivariable Model-Building: A Pragmatic Approach to Regression Analysis based on Fractional Polynomials for Modelling Continuous Variables , 2008 .

[18]  M. Metra,et al.  Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. , 2003, Journal of the American College of Cardiology.

[19]  R. Klapdor,et al.  CA 125 and its relation to cardiac function. , 1999, American heart journal.